Dong-A ST has begun to develop a new improved drug avoiding the patent of Viread
As Dong-A ST has acquired approval to conduct a clinical study for a new improved drug of the blockbuster hepatitis B treatment, Viread(generic name: tenofovir) and started its product development.
The Ministry of Food and Drug Safety has approved a Phase 1 clinical study to directly compare a D...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
